Generic Name: raloxifene

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Hormone Therapy Medications

Company: Eli Lilly

Approval Status: Approved

Generic Version Available: Yes

Experimental Code: N/A

Drug Indication

Evista is a selective estrogen receptor modulator approved for the prevention of breast cancer in high-risk postmenopausal women and women with osteoporosis (bone loss). It is not approved for the treatment of invasive breast cancer or to reduce the risk of cancer recurrence.

General Info

The female hormone estrogen promotes the growth of hormone receptor-positive breast cancer. Evista works blocking these receptors and preventing estrogen from binding to cancer cells. It has selective activity against breast cancer while having estrogen-like activity elsewhere in the body. Like estrogen, it can help reduce bone loss after menopause. It was approved in 1997.


Dosing Info:

Evista is taken as a once-daily tablet.

Side Effects

Common side effects include hot flashes, muscle and joint pain and swelling. Potential serious side effects may include stroke, blood clots and pulmonary embolism. Evista should not be used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: December 6, 2018